Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Coultreon Biopharma

Coultreon Biopharma

Series AUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$125Msum of rounds with a disclosed amount only
Named investors
8
Financing history
1 rounds
  1. Apr 28, 2026
    Series A · $125M (disclosed)
    Sofinnova Investments, Inc. (lead) via Maha KatabiGalapagos (participant)Regeneron Ventures (participant)Balyasny Asset Management L.P. (participant)Luma Group (participant)Samsara Biocapital, LLC (participant)Longwood Fund (participant)Finchley Healthcare Ventures (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipeline”
Investors on record
8 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Apr 28, 2026
    Coultreon Biopharma announced Series A of $125,000,000, led by Sofinnova Investments
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company